ascopubs.org

Quality-of-life assessment in patients with malignant ascites: Results of a multicenter phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone.

Association between a validated symptom assessment tool and nurse clinical impression in patients with cancer admitted to a palliative care unit. This is an ASCO Meeting Abstract from the 2011 ASCO ...
The Globe and Mail

Malignant Ascites Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Clover Biopharmaceuticals

DelveInsight’s, “Malignant Ascites Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Malignant Ascites pipeline landscape. It covers the ...